Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The relationship between premenstrual affective syndrome and psychiatric disorder was investigated, using 81 women presenting to a Neurology Clinic with functional headache. Premenstrual affective syndrome was significantly associated with a history of depressive syndrome in the population studied. Patients judged to have a non-affective psychiatric disorder reported no greater frequency of definite or probable premenstrual affective syndrome than patients considered psychiatrically normal. The premenstrual occurrence or exacerbation of affective symptoms has been noted. This symptom exacerbation maybe sufficient to require hospitalization. Data presented by Coppen indicate that women with affective disorder are more likely to report the premenstrual symptom of depression than women with other psychiatric disorders. These findings suggest that there may be some relationship between depressive disorder and premenstrual affective symptoms. As part of a larger study on the personality and psychiatric correlates of functional headache, data on the relationship between depressive syndrome and premenstrual affective symptoms were obtained.
 ...
PMID:Premenstrual affective syndrome and psychiatric disorder. 94 81

Chronic fatigue syndrome (CFS), which is characterized by devastating fatigue, mild fever, lymphadenopathy, headache, myalgia, insomnia and neuropsychiatric disorders, now has drawn much attentions from many physicians, researchers and even peoples in general society world wide. The pathogenesis of CFS is still remains to be clarified and clinico-pathological difference between CFS and mood disorder is controversial. In this paper, CFS would be reviewed in detail.
 ...
PMID:[Chronic fatigue syndrome]. 161 75

Using computed tomography, lateral ventricular size was determined in 45 schizophrenic and 22 affective disorder patients, and was found in both patient groups to be greater than that of 62 similarly aged headache controls. While drug-free, the 15 schizophrenics with ventricles 1 standard deviation greater than the age-corrected control mean tended to have less positive symptomatology than the 30 schizophrenics with smaller ventricles. There was no differences between these two schizophrenic groups in negative symptomatology. Amongst the depressed affective disorder patients, those with larger ventricles tended to be diagnosed as psychotic more often than those with smaller ventricles. Response to neuroleptic treatment was assessed in the 35 schizophrenics who had received conventional neuroleptics for at least 5 weeks. Those schizophrenics with ventricles 2 standard deviations greater than the age-corrected control mean showed less improvement than those with smaller ventricles and on some measures appeared to deteriorate. No such relationship between ventricle size and drug response could be detected in the affective disorder patients.
 ...
PMID:Lateral ventricular size, psychopathology, and medication response in the psychoses. 614 30

A retrospective study of 557 outpatients who had been treated with imipramine has been undertaken in a neuro-psychiatric unit. The usual dose was 75 mg per day, most often associated with other psychotropic drugs. The main indication was a depressive state for 75 p. c. of the patients: in that case the efficacy reached 65 p. c. The achievement of such results with moderate doses might indicate a possible relationship between the optimal dosage of the antidepressive drug and the intensity of the mood disorder. 12.5 p. c. of the patients were treated for a post-contusional syndrome. The best results have been obtained with early treatment when patients didn't have any loss of consciousness at the time of their contusion. The other successful indications of imipramine were phobic and hypocondriacal neurotic symptoms and functional headaches which were resistant to the usual treatments, raising the problem of a possible masked depression.
 ...
PMID:[Imipramine and neuro-psychiatry. Retrospective study of 557 out-patients treated in a neuro-psychiatric unit (author's transl)]. 709 71

The association between major depressive disorder (MDD) and self-reported histories of specific physical illnesses was investigated in 320 controls and 1968 first-degree relatives and 254 spouses of probands in the NIMH Collaborative Depression study. The Schedule for Affective Disorders and Schizophrenia-Lifetime Version was used to assign Research Diagnostic Criteria (RDC) diagnoses and a structured self-report instrument was used to assess lifetime medical history. Lifetime MDD was diagnosed in 914 subjects, 402 of whom had been hospitalized or received somatic treatment ('treated' MDD). Strong associations were observed between MDD (either treated or untreated) and both frequent/severe headaches and migraine headaches. There was a marked gender effect such that the relative odds for a woman with treated MDD to report migraine were over 5:1. Other associations were found between MDD and skin infections, respiratory illness, ulcer, hypotension, and diabetes. This is the largest non-patient sample using standardized assessment of mental disorders by direct interview in which associations between specific physical illnesses and MDD have been demonstrated. Implications for clinical practice and neurobiological research in depression are discussed.
 ...
PMID:Association between major depressive disorder and physical illness. 823 81

The recently developed Tridimensional Personality Questionnaire (TPQ) was used to examine personality correlates in women diagnosed with premenstrual syndrome (PMS). The hypotheses were that the TPQ scores, specifically harm avoidance (HA), would be higher in PMS subjects than in the general population but lower than in depressed populations because major mood disorder is an exclusion from the PMS diagnosis; harm avoidance would have the strongest association with PMS, but other TPQ factors might characterize nondysphoric subgroups in the PMS population. The sample included 157 women who sought medical treatment and met clearly defined criteria for PMS. Two comparison groups of age-matched women with major depression (MDD, N = 20) and premenstrual exacerbation of major depression (MDD + PMS, N = 24) were also evaluated. TPQ scores were significantly higher for PMS subjects on all three dimensions compared with external normative TPQ data. The TPQ dimensions of HA and novelty seeking (NS) were modestly correlated with the premenstrual symptom scores. The HA dimension correlated with premenstrual depression and physical aches; high NS scores correlated with premenstrual food cravings, headache, and mood swings. As hypothesized, the HA scores were significantly higher in the comparison groups diagnosed with major depression; the NS and reward dependence (RD) dimensions did not differ between the PMS and MDD groups. PMS was associated with only modest nonnormative personality correlates, as assessed by the TPQ. Elevations of the HA and NS dimensions were associated with a tendency for the PMS to present with specific symptom patterns: depressive symptoms for the HA factor and food cravings and mood swings for the NS factor. Further research employing other assessment methods is needed to confirm these findings.
 ...
PMID:Personality factors in women with premenstrual syndrome. 855 36

Since 1984, there has been a great interest in the phenomenon of a particular seasonally recurrent mood disorder called seasonal affective disorder (SAD) or winter depression and its treatment: the phototherapy. Seasonal affective disorder is a syndrome described by Rosenthal in 1984. This mood disorder is characterized by depression with onset recurrent in autumn or winter and spontaneous spring or summer remission. It is associated with hypersomnia, anergia, increased appetite, weight gain and carbohydrate craving. The population prevalence in the north of the USA is estimated between 3 and 5%, but it changes with sex, age and also latitude. A long time ago, we know that animals are photoperiod sensitive and that the melatonin secretion in mammals is suppressed by the light. In 1980, Czeiler reported for the first time that human melatonin secretion can be suppressed by high light exposure (+/- 1500 lux). In 1982, Rosenthal, Lewy and al. reported an antidepressant effect of light exposure of a manic-depressive patient. The phototherapy was born. To treat the SAD, the most common procedure of phototherapy is to expose the subject during 2 hours early in the morning, between 06:00 and 09:00 AM. The subject is sitting before a light screen, he can work and has to fix the screen one time every minute. The most common side effects are headache, eyestrain, muscle pain. The ocular phototoxicity is controversed and it seems to be potentially dangerous if phototherapy is associated with tricyclic antidepressants, neuroleptics and other medication containing a tricyclic, heterocyclic or porphyrin ring system. Since this finding, many questions are asked about photoperiod and its effects in the human being. Lewy proposes for the winter depression the hypothesis of a phase delayed circadian rhythm, that can be treated by a morning light exposure. At the present time, many trials are going on to study the effects of phototherapy in other problems like insomnia, maladaptation to night work, jet lag and Alzheimer disease.
 ...
PMID:[Seasonal affective syndrome and phototherapy: theoretical concepts and clinical applications]. 868 79

The effectiveness and safety of ECT in pharmacotherapy-refractory depression was examined in 11 hospitalized adolescents (ages 16.3 +/- 1.7 years, 10 females) with a primary DSM-III-R diagnosis of mood disorder, which had failed to respond to three or more adequate trials of antidepressant pharmacotherapy. After a thorough diagnostic evaluation, patients received a course of ECT involving 11.2 +/- 2.0 (range 8-15) administrations. ECT was commenced with bilateral treatment in 2 adolescents and nondominant right electrode placement in 9 patients; 5 of the 9 patients were subsequently changed to bilateral treatment. All 11 patients improved to a clinically significant degree. Significant improvements were noted in scores on the Children Depression Rating Scale-Revised (CDSR-R) and the Global Assessment of Functioning Scale (GAF) (p < 0.05). Euthymia, defined as CDRS-R score < or = 40, was achieved by 64% (7/11) of patients. The Mini-Mental State Examination showed no significant decline in cognitive functioning. Neuropsychological testing completed in 5 subjects both before ECT and 1-5 days after the last treatment, indicated a significant decline in attention, concentration, and long-term memory search. Minor side effects, experienced within the first 12 hours of treatment, were headache (80% of patients) and nausea/vomiting (64%). The potentially serious complication of tardive seizure (after full recovery of consciousness) occurred in 1 adolescent. Prolonged seizures (> 2.5 minutes) were noted in 7 of the 11 patients (9.6% of the 135 ECT administrations). Pending further research on ECT in youth, it is recommended that ECT should only be administered to youth in hospital settings, that all regularly administered psychotropic medications (including antidepressants) be discontinued before ECT and restarted after the final administration of ECT, and that physicians be aware that 12 treatments are usually sufficient, but that 15 treatments may occasionally be necessary for treating depressed adolescents. With the understanding that scientific evaluation of ECT in youth is lacking, it appears that ECT can be an effective and relatively safe treatment for depressed adolescents who have failed to respond to antidepressant pharmacotherapy.
 ...
PMID:Electroconvulsive treatment in adolescents with pharmacotherapy-refractory depression. 923 19

The authors prospectively assessed symptoms induced by the interruption of antidepressants in 16 patients (11 women and 5 men), aged from 33 to 85 years (mean = 52.4 +/- 16.4), treated with antidepressants since at least two weeks. All patients were free of alcohol abuse or dependence disorder and of other dependence to psychoactive substances. None of them presented medical illness. Diagnosis were made by separate evaluations by two authors and confirmed with a semistructered assessment instrument: the Schedule for Affective Disorders and Schizophrenia (Lifetime Version). All patients were submitted to a brutal discontinuation of their antidepressant agent. Patients were assessed twice, before the interruption of the antidepressant, and 72 hours later. Effects of antidepressant interruption were assessed by several means. Modification of anxiety and depression were evaluated using the Montgomery Asberg Depression Rating Scale (MADRS) and the Hamilton Anxiety Scale. Symptoms of withdrawal were assessed with Cassano and al.'s scale SESSH including an evaluation of anxiety, agitation, irritability, anergy, difficulty on concentrating, depersonalization, sleep and appetite disorders, muscle pains, nausea, tremor, sweating, altered taste, hyperosmia, paresthesias, photophobia, motor incoordination, dizziness, hyperacousia pain, delirium. Fourteen of the 16 patients (87.5%) presented modifications of their somatic or psychic state 3 days after the interruption of the antidepressant treatment. Most frequent symptoms were: increase in anxiety (31%), increase in irritability (25%), sleep disorders (19%), decrease of anergia and fatigue (19%). Mean scores of anxiety and depression were not significantly modified by the withdrawal. Following TCAs interruption (7 patients) most frequent symptoms were sleep disorders; increase in anxiety, nausea. Among patients withdrawn from SSRIs (6 patients), most frequent symptoms were increase in anxiety, increase in irritability, headache. Patients also presented a decrease of nausea, and of anorexia.
 ...
PMID:[Prospective evaluation of antidepressant discontinuation]. 969 14

There is a well-known association between migraine and affective disorders, but the information is sparse concerning the prevalence of migraine in subgroups of the affective disorders. The present study was undertaken to investigate the prevalence of migraine in unipolar depressive, bipolar I and bipolar II disorders. Patients with major affective disorders (n = 62), consecutively admitted to an open psychiatric ward, were examined with a semi-structured interview based on DSM-IV diagnostic criteria, combined with separate criteria for affective temperaments. Diagnosis of unipolar and bipolar I disorders followed the DSM-IV criteria, while bipolar II disorder encompassed patients with either discrete hypomanic episodes or a cyclothymic temperament. Migraine was diagnosed according to IHS-criteria. Symptoms of migraine were found to be common in these patients, both in those with unipolar depression (46% prevalence of migraine) and in those with bipolar disorders (44% prevalence). Among the bipolar patients there was, however, a striking difference between the two diagnostic subgroups, with a prevalence of 77% in the bipolar II group compared with 14% in the bipolar I group (P = 0.001). These results support the contention that bipolar I and II are biologically separate disorders and point to the possibility of using the association of bipolar II disorder with migraine to study both the pathophysiology and the genetics of this affective disorder.
Cephalalgia 2001 Nov
PMID:The prevalence of migraine in patients with bipolar and unipolar affective disorders. 1190 83


1 2 3 4 5 Next >>